Dopamine Receptor Agonists
- Summary
- Researchers at Purdue University have developed a class of novel D1 dopamine agonists, or stimulants, which may be useful in treating the symptoms of Parkinson's disease and other working memory and cognitive deficits. This series of compounds has potent and selective activity at dopamine D1 receptors, making them useful therapeutic agents in hypodopaminergic conditions. Recent studies have also shown that dopamine D1 agonists are able to reverse drug-induced and age-related deficits in working memory.
- Technology Benefits
- Novel class of dopamine agonists Potent and selective activity Clinical precedent
- Technology Application
- Pharmaceutical companies
- Detailed Technology Description
- David NicholsPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- Europe
- Application No.
- EP2421862
- *Abstract
-
- *Background
- Dopamine is a neurotransmitter that is important in locomotor control, reward circuitry, cognitive function, prolactin release, and a variety of other key physiological functions. Dopaminergic dysfunctions have been implicated in many disorders including Parkinson's disease, schizophrenia, addiction, and ADHD. Dopamine receptor agonists are of interest in terms of finding successful therapies for these disorders. However, current D1 and D2 receptor agonists can have adverse side effects depending on the level and timing of use.
- *IP Issue Date
- Jun 11, 2014
- *IP Type
- Utility
- *Stage of Development
- Proof of concept
- *Web Links
- Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipDavid NicholsPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
